| Literature DB >> 31284699 |
Jonas Abo Basha1, Matthias Kiel2, Dennis Görlich3, Katharina Schütte-Nütgen1, Anika Witten4, Hermann Pavenstädt1, Barbara C Kahl5, Ulrich Dobrindt6, Stefan Reuter7.
Abstract
Urinary tract infection (UTI), frequently caused by uropathogenic Escherichia coli (UPEC), is the most common infection after kidney transplantation (KTx). Untreated, it can lead to urosepsis and impairment of the graft function. We questioned whether the UPEC isolated from KTx patients differed from the UPEC of non-KTx patients. Therefore, we determined the genome sequences of 182 UPEC isolates from KTx and control patients in a large German university clinic and pheno- and genotypically compared these two isolated groups. Resistance to the β-lactams, trimethoprim or trimethoprim/sulfamethoxazole was significantly higher among UPEC from KTx than from control patients, whereas both the isolated groups were highly susceptible to fosfomycin. Accordingly, the gene content conferring resistance to β-lactams or trimethoprim, but also to aminoglycosides, was significantly higher in KTx than in control UPEC isolates. E. coli isolates from KTx patients more frequently presented with uncommon UPEC phylogroups expressing higher numbers of plasmid replicons, but interestingly, less UPEC virulence-associated genes than the control group. We conclude that there is no defining subset of virulence traits for UPEC from KTx patients. The clinical history and immunocompromised status of KTx patients enables E. coli strains with low uropathogenic potential, but with increased antibiotic resistance to cause UTIs.Entities:
Keywords: UPEC; Uropathogenic E. coli; antibiotic resistance; genomics; kidney transplantation; phylogeny; virulence traits
Year: 2019 PMID: 31284699 PMCID: PMC6678207 DOI: 10.3390/jcm8070988
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Clinical data.
|
| |||
|
|
|
| |
| Sex (female/male) | 49 (79%)/13 (21%) | 74 (70.5%)/31 (29.5%) | 0.1512 |
| Age (mean/median/σ in yr) | 56.67/58.75/15.09 | 53.45/ 55/21.82 | 0.2902 |
| BMI (mean/median/σ) | 26.19/26.03/4.58 | 24.62/24.21/4.41 |
|
| Hypertension (%) | 80.6% | 35.3% |
|
| Diabetes mellitus (%) | 21% | 14.7% | 0.3922 |
| Immunosuppression (%) | 100% | 9.7% |
|
| Previous tumor diagnosis (%) | 0% | 10.7% |
|
| Time from last KTx to UTI (mean/median/σ in yr) | 5.4/3.2/6.2 | - | - |
| Ureteral stent or urinary catheter (%) | 16.1% | 5.8% | 0.0539 |
| Lower UTI (%) | 80.3% | 80.4% | 1 |
| Upper UTI (%) | 19.7% | 19.6% | 1 |
| eGFR (mean/median/σ in mL/min) | 58.4/54.45/32.48 | 70.21/66.5/35.67 |
|
| Acute kidney injury (%) | 28.3% | 23.1% | 0.5658 |
| Hospitalization | 24.5% | 39.3% | 0.0527 |
|
| |||
| Hospitalization | 40.3% | 20% | 0.0068 |
| Surgery | 21% | 10.5% | 0.0709 |
| Ureteral stent or urinary catheter | 29% | 12.4% | 0.0125 |
|
| |||
| Beta-lactam | 6.5% | 1.9% | 0.1961 |
| Cephalosporine | 25.8% | 4.8% | 0.0002 |
| Fluoroquinolone | 9.7% | 2.9% | 0.0787 |
| Trimethoprim/ Sulfonamide | 30.6% | 2.9% | 0 |
| Fosfomycin | 11.3% | 2.9% | 0.0401 |
| Carbapenem | 0% | 1% | 1 |
|
| |||
| Prophylaxis | 29% | 4.8% | 0 |
| UTI | 25.8% | 7.6% | 0.0024 |
| Other infection | 12.9% | 7.6% | 0.2855 |
σ = standard variation, BMI= body mass index, eGFR = estimated glomerular filtration rate, KTx = kidney transplantation, p-values were obtained using t-test.
Figure 1Phylogenetic diversity of the UPEC isolated from KTx and control patients. The neighboring joining tree is based on the MLST of seven housekeeping genes performed with Ridom SeqSphere+ (https://www.ridom.de/seqsphere/) and was created with iTOL (https://itol.embl.de/). The sequence type (ST), the corresponding phylogroup and the isolate group is indicated for each UPEC isolate. The allocation to the two isolate groups (KTx or control) is indicated by different colors. Phylogenetic diversity of UPEC isolated from KTx and control patients. The neighboring joining tree is based on the MLST of seven housekeeping genes and was created with the Ridom SeqSphere+ (https://www.ridom.de/seqsphere/). The sequence type (ST), the corresponding phylogroup and the isolate group (KTx patient yes or no) is indicated for each UPEC isolate. The allocation to different phylogroups is indicated by different colors.
Distribution of phylogroups in relation to KTx and control UPEC isolates.
| Phylogroup | Total | KTx | Controls |
| ||
|---|---|---|---|---|---|---|
| No. of Isolates | No. of Isolates | % | No. of Isolates | % | ||
| A | 25 | 16 | 22.5 | 9 | 8.1 |
|
| B1 | 24 | 10 | 14.1 | 14 | 12.6 | 0.4706 |
| B2 | 88 | 27 | 38 | 61 | 55 |
|
| C | 8 | 1 | 1.4 | 7 | 6.3 | 0.1117 |
| D | 23 | 9 | 12.7 | 14 | 12.6 | 0.5805 |
| E | 2 | 2 | 2.8 | 0 | 0 | 0.1509 |
| F | 10 | 5 | 7 | 5 | 4.5 | 0.3389 |
| Clade V | 2 | 1 | 1.4 | 1 | 0.9 | 0.6293 |
No. = number, KTx = strains of kidney transplanted patients, p-values were obtained using Fisher’s exact test.
Distribution of O serotypes in relation to KTx and control UPEC isolates.
| Serogroups | Total | KTx | Controls |
| ||
|---|---|---|---|---|---|---|
| No. of Isolates | No. of Isolates | % | No. of Isolates | % | ||
| O2 | 14 | 5 | 7 | 9 | 7.1 | 0.5159 |
| O4 | 8 | 3 | 4.2 | 5 | 5 | 0.6187 |
| O6 | 20 | 3 | 4.2 | 17 | 15.2 |
|
| O8 | 18 | 7 | 9.9 | 11 | 9.8 | 0.6013 |
| O15 | 10 | 6 | 8.5 | 4 | 3.6 | 0.1435 |
| O16 | 5 | 2 | 2.8 | 3 | 2.7 | 0.6485 |
| O25 | 11 | 4 | 5.6 | 7 | 6.3 | 0.5608 |
| O83 | 5 | 1 | 1.4 | 4 | 3.6 | 0.3515 |
| O89 | 10 | 7 | 9.9 | 3 | 2.7 |
|
| not typeable | 21 | 10 | 14.1 | 11 | 10 | nd |
| other serotypes | 60 | 23 | 32.4 | 31 | 33.9 | nd |
No. = Number, KTx = strains of kidney transplanted patients, nd = not determined, p-values were obtained using Fisher’s exact test.
Figure 2Heatmap displaying the distribution of virulence factors present in KTx and control UPEC isolates. Each row represents one virulence factor. The prevalence of each virulence factor (VF) in KTx and control strains is coded by a color gradient. Vertical black and grey bars indicate the functional VF group: CU-fimbriae = chaperone-usher fimbriae, T2SS = type 2 secretion system, T3SS = type 3 secretion system, T5SS = type 5 secretion system, T6SS = type 2 secretion system. The color code indicates the prevalence of the corresponding VF (calculated as percentage) in the KTx and control group, respectively.
Distribution of resistance genes (RGs) present in relation to KTx and control UPEC isolates.
| Antibiotic | >1 RGs present | No RGs present |
| |||
|---|---|---|---|---|---|---|
| No. of Isolates | % | No. of Isolates | % | |||
| Beta-Lactam | KTx | 42 | 59.2 | 29 | 40.8 |
|
| Controls | 41 | 36.9 | 70 | 63.1 | ||
| Trimethoprim | KTx | 34 | 47.9 | 37 | 52.1 |
|
| Controls | 31 | 27.9 | 80 | 72.1 | ||
| Sulfonamides | KTx | 35 | 49.3 | 36 | 50.7 | 0.0763 |
| Controls | 40 | 36.0 | 71 | 64.0 | ||
| Fosfomycin | KTx | 0 | 0.0 | 71 | 100 | 1 |
| Controls | 1 | 0.9 | 110 | 99.1 | ||
| Fluoroquinolones | KTx | 3 | 4.2 | 68 | 95.8 | 1 |
| Controls | 6 | 5.4 | 105 | 94.6 | ||
| Aminoglycosides | KTx | 42 | 59.2 | 29 | 40.8 |
|
| Controls | 44 | 39.6 | 67 | 60.4 | ||
No. = number, KTx = strains of kidney transplanted patients, RG = resistance gene, nd = not determined, p-values were obtained using Fisher’s exact test.
Susceptibility patterns of KTx and control UPEC isolates.
| Antibiotic | Susceptible | Intermediate | Resistant |
| ||||
|---|---|---|---|---|---|---|---|---|
| No. of Isolates | % | No. of Isolates | % | No. of Isolates | % | |||
| Beta- Lactam (AMP+AMX) | KTx | 27 | 38 | 0 | 0 | 44 | 62 |
|
| Controls | 69 | 62.2 | 0 | 0 | 42 | 37.8 | ||
| Beta- Lactam + inhibitor (SAM) | KTx | 50 | 70.4 | 0 | 0 | 21 | 29.6 | 0.1734 |
| Controls | 88 | 79.3 | 0 | 0 | 23 | 20.7 | ||
| Beta- Lactam (CFX) | KTx | 58 | 81.7 | 0 | 0 | 13 | 18.3 | 0.2147 |
| Controls | 98 | 88.3 | 0 | 0 | 13 | 11.7 | ||
| Trimethoprim | KTx | 33 | 50 | 0 | 0 | 33 | 50 |
|
| Controls | 70 | 72.9 | 0 | 0 | 26 | 27.1 | ||
| TMP/SMX | KTx | 37 | 52.1 | 0 | 0 | 34 | 47.9 |
|
| Controls | 78 | 70.3 | 0 | 0 | 33 | 29.7 | ||
| Fosfomycin | KTx | 66 | 98.5 | 0 | 0 | 1 | 1.5 | 1 |
| Controls | 96 | 98 | 0 | 0 | 2 | 2 | ||
| Fluoroqinolones (CIP+LVX) | KTx | 55 | 77.5 | 1 | 1.4 | 15 | 21.1 | 0.6588 |
| Controls | 92 | 82.9 | 1 | 0.9 | 18 | 16.2 | ||
| Aminoglycosides (GEN) | KTx | 66 | 93 | 0 | 0 | 5 | 7 | 0.4637 |
| Controls | 106 | 95.5 | 0 | 0 | 5 | 4.5 | ||
No. = number, KTx = strains of kidney transplanted patients, AMP = ampicillin, AMX = amoxicillin, SAM= ampicillin/sulbactam, CFX = Cefuroxime, TMP = trimethoprim, SMX = sulfamethoxazole, CIP = ciprofloxacin, LVX = levofloxacin, GEN = gentamicin, p-values were obtained using Fisher’s exact test.
Distribution of the most frequent plasmid replicon types in relation to KTx and control UPEC isolates.
| Plasmid Type | Total | KTx | Controls |
| ||
|---|---|---|---|---|---|---|
| No. of Isolates | % | No. of Isolates | % | |||
| IncFIA | 24 | 10 | 14.1 | 14 | 12.6 | 0.4706 |
| IncFIB | 114 | 49 | 69 | 65 | 58.6 | 0.1025 |
| IncFIC | 27 | 16 | 22.5 | 11 | 9.9 |
|
| IncFII | 100 | 40 | 56.3 | 60 | 54.1 | 0.4411 |
| IncI1 | 33 | 17 | 23.9 | 16 | 14.4 | 0.0773 |
| IncQ1 | 20 | 13 | 18.3 | 7 | 6.3 |
|
| Col156 | 35 | 9 | 12.7 | 26 | 23.4 | 0.0526 |
| Other replicons | 68 | 30 | 42.3 | 38 | 34.2 | 0.1751 |
| None | 33 | 7 | 9.9 | 26 | 23.4 |
|
No. = number, KTx = strains of kidney transplanted patients, p-values were obtained using Fisher’s exact test.
Figure 3Phenotypic characteristics of the KTx and control UPEC isolates. The percentage of strains phenotypically tested positive for the expression of α-hemolysin, type 1 fimbriae and bacteriocins killing E.coli DH5α has been compared between the KTx and control groups.
Figure 4Expression of biofilm morphotypes in KTx and control UPEC isolates. The percentage of strains expressing different biofilm morphotypes at different growth temperatures is compared between the KTx and control groups.